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Epidermal growth factor receptor inhibitors
(EGFRi) are a class of targeted antineoplastics used
for the palliative treatment of aggressive squamous
cell cancers of skin (SCCS). Most reports describe the
monoclonal antibody, cetuximab, or the small
molecule, gefitinib.1-6 Response rates of SCCS to
EGFRi are high, with complete response (CR) not
uncommon. The molecular basis for susceptibility of
SCCS to EGFRi remains unknown. A report found no
EGFR mutations in SCCS of patients treated with
gefitinib.1
Erlotinib is an orally available EGFRi approved for
the treatment of lung and pancreatic cancer. Here we
describe the courses of 5 patients with recurrent/
unresectable or metastatic SCCS who had palliative
benefit from erlotinib. We also report the results of
EGFR mutational analysis of their archived tumors.
One of these patients was reported on previously in
an abstract.2METHODS
Institutional Review Board approval was obtained
for chart review and archival tumor analysis.
Specimens were analyzed using the ResponseDX
test (Response Genetics Inc, Los Angeles, CA).CASE SERIES
Case 1
A 60-year-old man with a history of remote
Hodgkin’s disease and multiple SCCS had metastases
to parotid and neck lymph nodes. Intravenousrtment of Hematology/Medical Oncology, Winship Cancer
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He began gefitinib in May 2004 with resolution of 1
disease site and stability of others, which were later
resected. In March 2006 he discontinued using
gefitinib after local progression. Resection was
attempted followed by various ineffective medical
treatments. In August 2007 he began erlotinib,
150 mg daily, with docetaxel, 75 mg/m2 every
3 weeks, receiving 8 cycles through February 2008
with response and clinical benefit. He continued
with erlotinib monotherapy until progression in May
2008. Erlotinib and taxanes were ineffective, and he
died in January 2009.
Case 2
A 54-year-old nonimmunosuppressed man with
SCCS of the face received radiation followed by
orbital exenteration and right side of the neck
dissection. He developed a submental mass and
posterior cervical adenopathy within 6 months and
was treated with cisplatin and radiation. Twomonths
after radiation, his submental mass recurred, and he
began erlotinib at 150mg daily with CR (Fig 1). There
was skepticism that this mass had actually beenUniversity School of Medicine, 550 Peachtree St; MOT 18, Atlanta,
GA 30308. E-mail: wread@emory.edu.
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Fig 1. Case 2. Submental recurrence of SCCS before (5/30/2006) and after (6/22/2006) erlotinib.
Fig 2. Case 2. Diffuse postoperative recurrence of SCCS before (1/30/207) and after (3/27/
2007) erlotinib.
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recurred and biopsy confirmed SCCS, erlotinib again
produced CR. In an attempt to clear his disease,
he underwent a resection of the mandible and
submental mass. By 6 weeks after surgery, there
was tumor growing from his wounds together with
new sites on the cheek. He restarted erlotinib, and
within 2 months again achieved CR of all evident
tumor sites (Fig 2). He did well on erlotinib for
8 months, with weight gain and improved quality of
life. On diffuse relapse in the skin and neck, he opted
to discontinue further treatment and died.
Case 3
A 91-year-old nonimmunosuppressed man with
multiple prior SCCS had multiple nodular metastases
in the parotid and adjacent skin and neck. He began
treatment with erlotinib at 150 mg daily in June 2010
achieving a near CR (Fig 3). Six months later
(December 2010) the remaining nodule began to
grow, and he underwent reirradiation with ongoing
erlotinib. His disease remained stable through June
2011 when he died from heart failure.
Case 4
A 38-year-old man with history of lung transplant
suffered multiple SCCS in the face. He underwentneck dissections in June 2005 followed by radiation
and carboplatin but suffered clinical progression in
the skin. Imaging showed multiple new lung
nodules, which proved to be SCCS on biopsy.
Immunosuppression was switched from tacrolimus
to sirolimus, and he began erlotinib at 150 mg daily.
Follow-up computed tomography showed a
marked reduction in the size and number of lung
metastases. Unfortunately, his extrapulmonary
cancers responded only transiently, and he died
from their continued progression. Computed
tomography performed shortly before his death
7 months later showed no evidence of progressive
cancer or pneumonitis in his lungs.Case 5
A 60-year-old nonimmunosuppressed man with a
history of a remote prior oral cancer had a rapidly
growing SCCS of the lip. Erlotinib was started at
150 mg daily while surgery was arranged. His tumor
regressed completely by day 14 (Fig 4). On resection,
only a 2-mm focus of tumor remained. Five months
later he had recurrence lateral to his previous site. He
began erlotinib at 75 mg daily (prior treatment
caused a rash) and had CR, leaving defects in the
skin where the tumor had been. He then received
Fig 3. Case 3. Diffuse regional recurrence of SCCS before (6/15/2010) and after (10/12/10)
erlotinib.
Fig 4. Case 5. New primary SCCS of skin of lip before (5/20/2007) and after (6/1/2007)
erlotinib.
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the erlotinib February 2009. Ten months later he had
a recurrence in the contralateral neck and restarted
erlotinib, 75 mg daily, with CR. On progression
5 months later, his dose was increased to 150 mg
with CR producing an extensive cavity in the tissues
of his neck. Because of declining performance status,
he discontinued his cancer treatment in September
2010 and died 1 month later.
RESULTS—MUTATIONAL ANALYSIS
All 5 tumor specimens were found to contain
wild-type EGFR.
DISCUSSION
In these patients with incurable SCCS, erlotinib
produced responses lasting months with palliative
benefit and low toxicity. It is not known why EGFRi
is active against SCCS. These EGFRi-responsive
tumors did not contain mutant EGFR. Perhaps the
normal EGFR pathway is important to SCCS because
of nonmutational amplification. Overexpression of
EGFR could explain the patient in case 5, whose
tumors progressed during erlotinib treatment butagain responded completely to a double dose.
Increased EGFR gene copy number has been
reported in SCCS.7,8
The mechanistic target of rapamycin (mTOR)
pathway is downstream from EGFR, and treatment
with the mTOR inhibitor, sirolimus, has been asso-
ciated with a reduced rate of new SCCS in transplant
patients as well as regression of some established
cancers.9 The mechanism by which sirolimus
accomplishes this is not known. One explanation is
that sirolimus accomplishes this by attenuating the
EGFR pathway. Other treatments operating along the
mTOR/EGFR axis might be beneficial for persons
suffering advanced or metastatic SCCS.
Even though erlotinib is less expensive and does
not require an infusion center, cetuximab is often
cheaper for the patient because of differences in
insurance coverage. Nevertheless, erlotinib should
be considered for off-label use in palliating advanced
SCCS.
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